Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 3/14/13 → 8/31/19 |
Funding
- PPD Development (GS-US-321-0102)
- Gilead Sciences, Inc. (GS-US-321-0102)
Protocol #GS-US-321-0102: A Phase 2b, Dose-Ranging, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of GS-6624, a Monoclonal Antibody Against Lysyl Oxidase Like 2 (LOXL2) in Subjects with Primary Sclerosing Cholangiti
- Flamm, Steven L (PD/PI)
Project: Research project